Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer halts global shipments of Chantix over contamination worries

By Brian Buntz | June 25, 2021

Pfizer logoPfizer (NYSE:PFE) has stopped international shipments of the smoking-cessation drug Chantix (varenicline) after concluding it had elevated levels of a potential carcinogen.

The substance in question, nitrosamines, are organic compounds thought to cause cancer in various organisms.

“We believe the benefits of Chantix/Champix outweigh the very low potential risks, if any, posed by nitrosamine exposure on top of other common sources over a lifetime,” said Pfizer spokesperson Steven Danehy. Champix is the brand name of Chantix outside of the U.S. “We are actively working with regulatory authorities around the world to communicate the appropriate information in accordance with specific actions and timing, which vary by country.”

Pfizer suspended distribution as a precaution. The company is also researching to determine whether additional lots of the drug contain nitrosamines.

STAT News first reported the news.

Earlier this month, health officials in Canada announced a recall of the drug known as Champix internationally. An announcement posted on a Canadian government website cited the presence of the “impurity N-nitrosovarenicline above the acceptable concentration limit” in an affected lot of the drug.

Chantix

Chantix image courtesy of Pfizer.

Nitrosamines are also present in various foods, including beer, cured and grilled meats, some vegetables and dairy products. Nitrosamines are also found in some drinking water.

FDA approved the smoking-cessation drug in 2006. The agency has indicated the medicine for a 12-week period but allows for an additional 12 weeks of therapy if needed.

Health authorities have not identified a cancer-related safety issue related to Chantix/Champix, yet continued smoking can lead to a tangible increase in cancer risk.

FDA is continuing to test a range of medicines for nitrosamines, which scientists have also identified in hypertension medications, leading to a series of recalls. Manufacturers across the pharma industry have also had ongoing programs to identify the presence or formation of nitrosamines in drugs.

Health authorities worldwide have identified acceptable daily limits for nitrosamines in medicines to maintain a theoretical excess cancer risk of 1 in 100,000 or lower. For context, between one in two and one in three people in many parts of the world will develop cancer at some point in their lives.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. ed silverman says

    June 26, 2021 at 5:29 pm

    This story was first reported by STAT but no credit was given..

    https://www.statnews.com/pharmalot/2021/06/24/pfizer-chantix-champix-smoking-nitrosamines/

    Reply
    • Brian Buntz says

      June 28, 2021 at 3:43 pm

      Thanks for flagging, Ed. There is a STAT credit line now. I also got some of the information from a Pfizer spokesperson.

      Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE